Jun 13 |
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
|
May 31 |
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
|
May 18 |
Q1 2024 Autolus Therapeutics PLC Earnings Call
|
May 17 |
Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript
|
May 17 |
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
|
May 17 |
Autolus Therapeutics GAAP EPS of -$0.24 misses by $0.09, revenue of $10.09M misses by $14.96M
|
May 17 |
Autolus Therapeutics Reports First Quarter 2024 Financial ResultsĀ and Business Updates
|
May 14 |
Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
|
May 14 |
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
|
May 13 |
Autolus Therapeutics Q1 2024 Earnings Preview
|